We are dedicated to the discovery and development of small molecule therapeutics targeting fundamental biological pathways of cancer. Our experienced team is comprised of industry leaders with proven track records in the discovery, clinical development, and commercialization of innovative cancer therapies. Leveraging our extensive industry experience and know-how, we developed our Integrated Discovery Engine—our working model for generating potentially differentiated product candidates that are designed to target distinct cancer pathways. This approach has allowed us to advance a diverse pipeline in a capital efficient manner, clearing four INDs with the FDA in five years. We believe our deep pipeline of oncology therapeutic candidates has the potential to significantly improve the lives of patients with various types of cancer.

In May 2020, we established Zentera Therapeutics, our majority-owned Chinese joint venture, to develop and commercialize three Zentalis-discovered oncology candidates (ZN-c5, ZN-c3, and ZN-d5), in addition to potential future candidates, in China. The launch of Zentera is a key milestone in our global clinical development strategy and is the first step toward advancing our potentially best-in-class therapeutic candidates to markets worldwide.